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Abstract
Background: Amongst Sardinians the human leukocyte antigen (HLA) DRB1-DQB1 haplotypes *15:02-*06:01, *16:
01-*05:02, *14:01-4-*05:03 are protective for multiple sclerosis (MS), while *13:03-*03:01, *04:05-*03:01, *03:01-*02:01,
*15:01-*06:02 and Mycobacterium avium subspecies paratubercolosis (MAP) are predisposing factors. We studied the
correlation between MAP and HLA.
Methods: Five hundred thirty-one patients were searched for anti-MAP2694 antibodies, DRB1-DQB1 genotyping
was performed. The haplotypes were classified as predisposing, neutral or protective.
Results: Anti-MAP2694 were found in 23 % of subjects carrying one protective HLA versus 32 % without (p = 0.04).
Conclusions: We showed a lower frequency of Abs in patients with protective HLA. These haplotypes could have a
protective role for both MS and MAP.
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Background
Multiple Sclerosis (MS) is a multifactorial disease shaped
by both genetic and environmental factors. In Sardinia,
an Italian island with a very high prevalence of the
disease, the genetics of MS have some peculiarities. In
particular, there is a negative association with the DRB1-
DQB1 human leukocyte antigen (HLA) haplotypes
*15:02-*06:01, *16:01-*05:02 and *14:01-4-*05:03 and a
positive association with *13:03-*03:01, *04:05-*03:01,
*03:01-*02:01 and *15:01-*06:02 [1]. The last of these is
the main genetic risk factor for MS in Northern European
populations, [2] it gives Sardinians a strong predisposition
to MS, but is very rare in this population [3]. Concerning
environmental factors, an association between MS and
Mycobacterium avium subspecies paratubercolosis (MAP)
was identified on the island [4]. MAP is an endocellular
pathogen, it is present in 39.2 % of patients and in
6 % of healthy controls (HC) in the Sardinian popula-
tion. It could be a trigger for the disease by means of
a molecular mimicry mechanism and the spreading of
epitopes [5].
In recent years, many studies have focused on the
possibility of a relationship between genetic and infec-
tious factors in conferring risk of MS, in particular between
predisposing HLA and Epstein-Barr virus (EBV) [6–8]. The
studies yielded conflicting results (negative interaction in
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the first study, and positive in two others). Other studies
aimed to investigate the influence of genotype on levels of
humoral response to EBV. Waubant et al. showed higher
levels of EBNA-1 antibodies (Abs) in HLA-DRB1 positive
patients [9]. Rubicz et al. used a genome-wide approach to
analyze the SNPs associated with EBV-related diseases,
finding an association between EBNA-1 Abs levels and
HLA [8].
There are no studies focused on the relationship
between HLA and MAP.
We aimed to search for possible relationships between
the presence of anti-MAP Abs and predisposing/protective
HLA in MS patients.
Methods
A group of MS patients, diagnosed according to McDonald
criteria 2010 [10], was enrolled in the study after giving in-
formed written consent. They were recruited randomly
from the MS center of the University of Cagliari, between
patients performing routine visits. The only inclusion cri-
terion was to have a diagnosis of MS (McDonald 2010)
and there were not exclusion criteria. In fact, in a previous
study, we did not find association between presence of
anti-MAP antibodies and clinical variables [5]. The
University of Cagliari ethical committee approved the
study and the informed consent. The clinical and
demographic variables are reported in Table 1. For each
subject a blood sample was collected and analyzed for
the presence of anti-MAP2694 Abs by indirect ELISA,
as previously described [4]. Moreover, DNA was extracted
to perform DRB1-DQB1 HLA genotyping and the haplo-
types were classified as predisposing (*13:03-*03:01,
*04:05-*03:01, *03:01-*02:01, *15:01-*06:02) or protective
(*15:02-*06:01, *16:01-*05:02, *14:01-4-*05:03), according
to the previous study [1]. Other haplotypes were con-
sidered neutral.
Statistical analysis
The Pearson’s chi squared test was used for the haplo-
types and genotypes analysis. For the former, protective
haplotypes versus neutral and predisposing were con-
sidered. The analysis was repeated considering neutral
and predisposing haplotypes together. In the genotypes
analysis, the presence of at least one protective haplo-
type versus its absence was evaluated.
Results
The study enrolled 531 patients, 372 females and 159
males (F:M = 2.3:1). MAP negative subjects carried a
total of 109 (15 %) protective, 317 (44 %) neutral and
296 (41 %) predisposing HLA haplotypes, while MAP
positive patients carried a total of 33 (11 %) protective,
140 (46 %) neutral and 133 (43 %) predisposing HLA
haplotypes (p = 0.19) Table 2. When considering protective
HLA versus combined neutral and predisposing ones,
MAP negative patients carried 613 (85 %) neutral or pre-
disposing and 109 (15 %) protective HLA haplotypes, while
MAP positive subjects carried 273 (89 %) neutral or predis-
posing and 33 (11 %) protective haplotypes (p = 0.07)
Table 3.
The analysis of the genotypes showed that the protective
alleles were carried by 134 patients. The number of
patients carrying at least one protective haplotype was 31
(20 %) in MAP positive and 103 (29 %) in MAP negative
patients (p = 0.05) Table 4.
Discussion
Sardinian MS patients have some genetic and environ-
mental peculiarities. They carried predisposing and pro-
tective haplotypes different from those carried by other
MS populations [1]. Moreover, nowadays, it is only in
Sardinia that the disease is associated with MAP infec-
tion [4, 5]. An interesting field of research is the possible
interaction between the HLA haplotypes and the pres-
ence of anti-MAP Abs in conferring MS risk. Recently, a
molecular modeling approach was used to find the dif-
ferences between the Sardinian predisposing (*03:01
and *15:01) and protective (*16:01 and *15:02) HLA in
Table 1 Clinical and demographic data of patients included in the study
Mean age Median EDSS Course Therapy Steroids
RR SP PP NONE IFN GA NAT FING MIX AZA
ALL 43 y 2.5 82 % 13 % 5 % 31 % 25 % 18 % 10 % 12 % 1 % 3 % 6 %
MAP + 41 y 2 81 % 15 % 4 % 29 % 27 % 17 % 10 % 13 % 0 % 4 % 5 %
MAP- 44 y 2.5 84 % 10 % 6 % 32 % 26 % 16 % 11 % 13 % 1 % 1 % 6 %
RR relapsing remitting, SP secondary progressive, PP primary progressive, IFN beta interferon, GA glatiramer acetate, NAT natalizumab, FING fingolimod, MIX
mitoxantrone, AZA azathioprine
Table 2 Analysis of haplotypes: protective versus neutral versus







Anti-MAP2694 Abs Negative 109 (15 %) 317 (44 %) 296 (41 %)
Positive 33 (11 %) 140 (46 %) 133 (43 %)
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recognizing MAP peptide. The former were found able
to bind the MAP peptide better than the protective
ones, suggesting a higher presentation efficiency, a
higher probability of T-cell activation and autoimmune
reaction [11].
In our study the analysis of the haplotypes showed no
significant difference in frequency of predisposing, pro-
tective and neutral haplotypes among MAP+ and
MAP- patients, suggesting that MAP infection and pre-
disposing haplotypes are independent risk factors. This
is in line with the study of De Jager et al., that analyzed
the association between EBV infection, evaluating the
levels of anti-EBNA-1 Abs and the presence of DRB1*1501
[6]. They concluded that both factors independently con-
tributed to an increased MS risk. In their study no predis-
posing HLA were considered [6].
On the other hand, Rubicz et al. analyzed 30 genome-
wide significant MS SNPs and found an association
between EBNA-1 quantitative trait and SNP rs9271366,
and between EBNA-1 serostatus trait (positive or negative)
and SNPs rs3129860 and rs3135388. All these SNPs are
located within HLA-DR and HLA-DQ genes, suggesting
that this region is important both for EBV-related and
autoimmune responses [8].
Sunqvist et al. found an interaction between EBNA:
385–420 IgG and the presence of DRB1*15. They con-
cluded that the mechanism through which HLA influ-
ences MS risk could involve the immune control of EBV
infection. They also evaluated the protective haplotype
A*02, demonstrating the interaction between its absence
and the presence of the same Abs [7].
This last point is in line with the findings in our study.
In fact, the analysis of haplotypes identified a trend towards
a lower frequency of Abs in patients with protective haplo-
types. The analysis of genotypes confirmed this finding,
showing a significantly lower presence of anti-MAP Abs in
patients carrying at least one protective HLA versus pa-
tients without.
We did not find an association between the presence
of Abs and predisposing HLA.
Conclusions
In conclusion, on the basis of our data, we could
hypothesize that both genetic and MAP have an inde-
pendent role in conferring MS risk.
Moreover, considering the demonstration of lower fre-
quency of anti-MAP Abs in patients with protective
HLA, it is possible that these haplotypes play a role in
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Table 3 Analysis of haplotypes: protective versus combined





Anti-MAP2694 Abs Negative 613 (85 %) 109 (15 %)
Positive 273 (89 %) 33 (11 %)
Table 4 Analysis of genotypes: Absence versus presence of at
least one protective haplotype. Pearson’s chi squared (p = 0.05)
Absence of protective
haplotypes




Negative 258 (71 %) 103 (29 %)
Positive 122 (80 %) 31 (20 %)
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